Trial Profile
Clinical Study on the Safety and Efficacy of Anti-PSMA CAR NK Cells in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Anti-PSMA-CAR-NK-cell-therapy-Allife-Medical-Science-and-Technology (Primary) ; Cyclophosphamide; Fludarabine
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Allife Medical Science and Technology
- 28 Jul 2022 Planned End Date changed from 1 Dec 2021 to 1 Jun 2024.
- 28 Jul 2022 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2023.
- 28 Jul 2022 Status changed from not yet recruiting to recruiting.